July 28, 2020
PAR-20-278 - NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
The purpose of this Notice is to correct the eligibility status of "Non-domestic (non-U.S.) components of U.S. Organizations" in Foreign Institutions under Eligible Applicants in PAR-20-278 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)".
The following text of Part 2. Full Text of Announcement, Section III. Eligibility Information, 1. Eligible Applicants, Foreign Institutions has been corrected (in italics):
Currently reads:
Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Should correctly read (italics):
Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
All other aspects of PAR-20-278 are unchanged.
Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: [email protected]
Christopher Hatch, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6454
Email: [email protected]
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]